<DOC>
	<DOCNO>NCT01140828</DOCNO>
	<brief_summary>The aim study determine whether rabeprazole superior placebo prevent dyspepsia gastroduodenal injury subject osteoarthritis ( OA ) and/or rheumatoid arthritis ( RA ) and/or bone pain .</brief_summary>
	<brief_title>A Study Rabeprazole Prevention Non Steroidal Anti-inflammatory Drug -Associated Gastroduodenal Injury</brief_title>
	<detailed_description>Non steroidal anti-inflammatory drug ( NSAIDs ) well know increase risk gastroduodenal ( GD ) ulcer complication . Up 40 % average-risk NSAID user suffer dyspepsia without endoscopic evidence gastroduodenal injury . It result significant loss productivity impairment Quality Life ( QoL ) . Proton pump inhibitor ( PPIs ) show effective prevent reduce NSAID-induced GD injury . PPIs believe class effect Rabeprazole , least expensive PPI , grossly under-utilized area . Current Hospital Authority ( HA ) guideline , however , endorse use PPI patient high risk ulcer bleed . Since NSAID-induced dyspepsia indication PPI accord HA guideline , patient receive PPI treatment .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<criteria>Outpatient inpatient subject clinical diagnosis OA RA bone pain Subjects expect require regular antiinflammatory therapy arthritis symptom management Subjects history peptic ulcer complication Screening test negative H pylorus Subjects test positive rescreened eradication H. pylori History gastrointestinal ( GI ) hemorrhage History gastric duodenal surgery Presence erosive esophagitis , gastricoutlet obstruction Likelihood require treatment study drug permit protocol Impaired hepatic function ( SGPT ( ALT ) serum glutamate oxaloacetate transaminase ( SGOT ) ( AST ) &gt; 2 x upper limit normal ) renal function ( serum creatinine &gt; 200 umol/l ) Any condition baseline finding , investigator 's judgment , might increase risk subject decrease chance obtain satisfactory data achieve study objective Anemia Hb &lt; 10 g/dL Suspected clinical diagnosis inflammatory bowel disease Congestive heart failure ( NYHA class III IV ) Subjects consider requirement continue use : Corticosteroids ( dose equivalent prednisolone/ prednisone &gt; 10mg daily stable dose ) diseasemodifying antirheumatic drug ( DMARDs ) ( unless stable dose ≥ 12 week ) Iron replacement therapy ( dose &gt; 15mg elemental iron/day ) Iron replacement therapy ( dose &gt; 15mg elemental iron/day ) supplement deficiency prevention ( dose ≤ 15mg elemental iron/day ) due anemia reason Double antiplatelet therapy ( e.g . aspirin + Plavix ) Anticoagulants Antiulcer medication , e.g . sucralfate , H2 receptor antagonist ( H2RAs ) , misoprostol , PPIs study medication Sucralfate , misoprostol regular H2 receptor antagonist ( H2RAs ) ( &gt; 3 days/week ) COX2 inhibitor antiulcer medication COX2 selective inhibitor screening allow treatment discontinue time</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Arthritis</keyword>
	<keyword>Bone pain</keyword>
	<keyword>dyspepsia</keyword>
</DOC>